Avacta still waiting on MHRA approval for Covid-19 test

Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

The AIM-traded firm said the submission had been made to the Medicines and Healthcare products Regulatory Agency (MHRA) by its partner Mologic.

“To date, neither Avacta nor Mologic have received any update from the MHRA,” the board said in its statement.

“Avacta will update the market when it is in a position to do so.”

At 0829 BST, shares in Avacta Group were up 0.81% at 245.97p.